Literature DB >> 15456944

Differential time course of effects of kappa-opioid agonist treatment on dynorphin A levels and kappa-opioid receptor density.

Claudio D'Addario1, Manuela Di Benedetto, Sari Izenwasser, Sanzio Candeletti, Patrizia Romualdi.   

Abstract

The effects of kappa-opioid agonist treatment on kappa-opioid receptor density and on dynorphin A levels in the rat brain were studied. Rats were treated with the selective kappa-opioid agonist U-69593 or vehicle for 5 d. Dynorphin A levels and kappa-opioid receptor binding were measured on day 8 (3 d after the last injection) or 22 (17 d after the last injection). On day 8, kappa-opioid receptor density was increased in the hypothalamus of rats treated with U-69593; there were no changes in the frontal cortex or caudate putamen. In contrast, there was an increase in dynorphin A levels in the frontal cortex and no changes in hypothalamus and caudate putamen in response to U-69593. On day 22, Bmax was decreased in frontal cortex and caudate putamen of U-69593-treated rats, whereas dynorphin A levels were increased in the caudate putamen and in the frontal cortex. These findings suggest that kappa-opioid receptor agonist treatment has long-term, continually changing effects on the kappa-opioid system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456944     DOI: 10.1385/JMN:24:2:307

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  51 in total

1.  Dopamine antagonist and "binge' cocaine effects on rat opioid and dopamine transporter mRNAs.

Authors:  R Spangler; Y Zhou; C E Maggos; A Zlobin; A Ho; M J Kreek
Journal:  Neuroreport       Date:  1996-09-02       Impact factor: 1.837

2.  Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist.

Authors:  C A Heidbreder; S Schenk; B Partridge; T S Shippenberg
Journal:  Synapse       Date:  1998-11       Impact factor: 2.562

3.  Changes in prodynorphin peptide content following treatment with morphine or amphetamine: possible role in mechanisms of action of drug of abuse.

Authors:  K A Trujillo; H Akil
Journal:  NIDA Res Monogr       Date:  1989

4.  Kappa opioid inhibition of morphine and cocaine self-administration in rats.

Authors:  S D Glick; I M Maisonneuve; J Raucci; S Archer
Journal:  Brain Res       Date:  1995-05-29       Impact factor: 3.252

5.  Role of extracellular dopamine in the initiation and long-term expression of behavioral sensitization to cocaine.

Authors:  C A Heidbreder; A C Thompson; T S Shippenberg
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

6.  Downregulation of kappa opioid receptor mRNA levels by chronic ethanol and repetitive cocaine in rat ventral tegmentum and nucleus accumbens.

Authors:  A Rosin; S Lindholm; J Franck; J Georgieva
Journal:  Neurosci Lett       Date:  1999-11-05       Impact factor: 3.046

7.  The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat.

Authors:  C A Heidbreder; S R Goldberg; T S Shippenberg
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

8.  Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum.

Authors:  J B Daunais; D C Roberts; J F McGinty
Journal:  Neuroreport       Date:  1993-05       Impact factor: 1.837

9.  Morphine alters preproenkephalin gene expression.

Authors:  G R Uhl; J P Ryan; J P Schwartz
Journal:  Brain Res       Date:  1988-09-06       Impact factor: 3.252

10.  Early changes in prodynorphin mRNA and ir-dynorphin A levels after kindled seizures in the rat.

Authors:  P Romualdi; A Donatini; G Bregola; C Bianchi; L Beani; S Ferri; M Simonato
Journal:  Eur J Neurosci       Date:  1995-09-01       Impact factor: 3.386

View more
  1 in total

Review 1.  Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence.

Authors:  Brendan M Walker; Glenn R Valdez; Jay P McLaughlin; Georgy Bakalkin
Journal:  Alcohol       Date:  2012-03-27       Impact factor: 2.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.